Effectiveness of tDCS on Reducing Craving in Patients Practicing Chemsex: a Single-center, Double-blind, Randomized Controlled Pilot Trial
NCT ID: NCT05945199
Last Updated: 2024-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
40 participants
INTERVENTIONAL
2024-07-29
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This treatment should therefore lead to a reduction in the craving for consumption of psychoactive substances and/or the practice of uncontrolled sexual activity.
The stakes of this new treatment are high, because chemsex exposes people to health risks for themselves and others. These risks include the risk of infection (skin infections, HIV infection, hepatitis viruses), psychological harms (anxiety attacks, depression, suicide risk), risk of addiction (addiction to the psychoactive product used, sex addiction), and toxicological harm (overdose, dangerous combination of psychoactive substances) or trauma (blows, trauma to the genitals or anorectal trauma).
To date, there is no proven therapeutic treatment for people wishing to reduce or stop chemsex.
40 participants will be randomized into 2 groups:
* 20 patients will receive active stimulation
* 20 patients will receive sham stimulation
The total duration of the study for each patient will be 13 weeks: 1 week of stimulation and 12 weeks of follow-up.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
tDCS to Decrease Opioid Relapse (UG3)
NCT03842137
Evaluation of the Effect of tDCS on Cannabis Craving
NCT04389528
Neuromodulation and Cognitive Training in Opioid Use Disorder
NCT03773523
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors
NCT03530800
The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories
NCT04871269
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tDCS active
tDCS
* 1 session/day for 5 consecutive days
* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group
Assessment of risk behaviours
Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
Scales
EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
Sham tDCS
tDCS
* 1 session/day for 5 consecutive days
* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group
Assessment of risk behaviours
Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
Scales
EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tDCS
* 1 session/day for 5 consecutive days
* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group
Assessment of risk behaviours
Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
Scales
EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient aged ≥ 18 years
* Patient motivated and willing to change chemsex behavior, assessed by examiner during screening and inclusion visits
* Patient using at least one of the following psychoactive substances to modify sexual performance and/or experience:
* Cathinones, or methamphetamine, or MDMA, or cocaine, or ketamine, or GBL/GHB
* ≥ 1 time per month over the past 6 months and/or ≥ 10 times over the past year
Exclusion Criteria
* Patient with a recent change (\< 1 month) in the prescription of a psychotropic treatment
* Patient presenting an acute psychiatric condition requiring hospitalization and/or immediate modification of a psychotropic treatment
* Patients with unstable or uncontrolled neuropsychiatric disease
* Patients with a history of epileptic seizures
* Patients with unexplained episodes of loss of consciousness, as this condition may be linked to cerebral alterations or epilepsy
* Patients with advanced or decompensated somatic pathology, requiring hospitalization expected during study follow-up
* Patients suffering from any serious life-threatening illness, such as congestive heart failure, chronic obstructive pulmonary disease or active neoplasia
* Patients with implanted cerebral medical devices, implanted pacemakers, or any electrically, magnetically or mechanically activated implant.
* Patients with cardiac, neural or drug implants
* Patients with vascular clips or other electrically sensitive support systems in the brain
* Patients with severe brain lesions
* Patients with skin lesions at stimulation sites
* Patients with skin problems such as dermatitis, psoriasis or eczema
* Patients with severe or frequent headaches
* Patients who have already benefited from tDCS sessions
* Pregnant, parturient or breast-feeding women (pregnancy test)
* Staff working in the addictology department of Dijon University Hospital
* Patient participating in another clinical trial
* Patient not affiliated to national health insurance
* Patient unable to complete assessment scales
* Patient under psychiatric care without consent or under legal protection (guardianship, curatorship)
* Major incapable or unable to provide consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PETIT AOI 2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.